IP Library › Granted Patent US 12,233,088
Granted Patent B2
US 12,233,088 · App. 17/821,786 · Granted Feb 25, 2025

Bis-choline tetrathiomolybdate for treating Wilson Disease

Inventors: Carl Bjartmar (Stockholm, SE); Karl-Heinz Weiss (Stockholm, SE); Michael Schilsky (Stockholm, SE); Frederick Askari (Stockholm, SE); Anna Czlonkowska (Stockholm, SE); Peter Ferenci (Stockholm, SE); Peter Hedera (Stockholm, SE); Aftab Ala (Stockholm, SE)
Assignee: Alexion Pharmaceutical, Inc.
A61K33/24A61K9/0053A61K9/28A61K31/14A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,088
App. No.
17/821,786
Granted
Feb 25, 2025
Kind
B2
Abstract

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected , alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

Claims (48)

1. A method of treating Wilson Disease in a patient, comprising administering bis-choline tetrathiomolybdate to the patient in need thereof in a fasted state.

2. The method of treating Wilson Disease according to claim 1 , wherein 15 mg of bis-choline tetrathiomolybdate is administered to the patient once daily.

3. The method of treating Wilson Disease according to claim 1 , wherein the bis-choline tetrathiomolybdate is administered to the patient as a delayed-release dosage form.

4. The method of treating Wilson Disease according to claim 1 , wherein 15 mg of bis-choline tetrathiomolybdate is administered to the patient once every other day.

5. The method of treating Wilson Disease according to claim 1 , wherein bis-choline tetrathiomolybdate administration is modified if the patient exhibits:

(1) an alanine aminotransferase (ALT) level at least twice that of the ALT level exhibited when starting bischoline tetrathiomolybdate treatment,

(2) an alanine aminotransferase (ALT) level of at least twice the upper limit of normal (ULN),

(3) a hemoglobin level of 70% or less than the hemoglobin level exhibited when starting bis-choline tetrathiomolybdate treatment,

(4) a platelet level of 70% or less than the platelet level exhibited when starting bis-choline tetrathiomolybdate treatment, or

(5) a neutrophils level of 70% or less than the neutrophils level exhibited when starting bis-choline tetrathiomolybdate treatment, wherein the bis-choline tetrathiomolybdate dose is reduced and wherein:

if the patient was on a 15 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 15 mg bis-choline tetrathiomolybdate every other day;

if the patient was on a 30 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 15 mg bis-choline tetrathiomolybdate once daily;

if the patient was on a 45 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 30 mg bis-choline tetrathiomolybdate once daily;

if the patient was on a 60 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 45 mg bis-choline tetrathiomolybdate once daily;

if the patient was on a 75 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 60 mg bis-choline tetrathiomolybdate once daily; or

if the patient was on a 90 mg once daily dose of bis-choline tetrathiomolybdate, reducing the dose to 75 mg bis-choline tetrathiomolybdate once daily.

6. The method of treating Wilson Disease according to claim 5 , wherein bis-choline tetrathiomolybdate administration is modified if the patient exhibits an alanine aminotransferase (ALT) level of at least twice the upper limit of normal (ULN).

7. The method of treating Wilson Disease according to claim 6 , wherein the ULN is 30-45 IU/mL.

8. The method of treating Wilson Disease according to claim 1 , wherein if the patient exhibits an abnormal test result the bis-choline tetrathiomolybdate is administered to the patient:

(a) at a first dose level comprising from about 15 to about 90 mg per day of bis-choline tetrathiomolybdate for a first time period, followed by

(b) at a second dose level comprising at least about 15 mg per day less of bis-choline tetrathiomolybdate than the first dose level for a second time period.

9. The method of treating Wilson Disease according to claim 8 , wherein:

(i) the first dose level comprises about 15 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 15 mg per two days of bis-choline tetrathiomolybdate; or

(ii) the first dose level comprises about 30 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 15 mg per day of bis-choline tetrathiomolybdate; or

(iii) the first dose level comprises about 45 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 30 mg per day of bis-choline tetrathiomolybdate; or

(iv) the first dose level comprises about 60 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 45 mg per day of bis-choline tetrathiomolybdate; or

(v) the first dose level comprises about 75 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 60 mg per day of bis-choline tetrathiomolybdate; or

(vi) the first dose level comprises about 90 mg per day of bis-choline tetrathiomolybdate and the second dose level comprises less than about 75 mg per day of bis-choline tetrathiomolybdate.

10. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises:

(i) an alanine aminotransferase (ALT) level of (1) at least twice that of a baseline ALT measured before bischoline tetrathiomolybdate administration or (2) greater than 68 IU/mL; or

(ii) a hemoglobin level of (1) 70% or less than a baseline hemoglobin level measured before bis-choline tetrathiomolybdate administration or (2) 70% or less than a normal hemoglobin level; or

(iii) a platelet level of (1) 70% or less than a baseline platelet level measured before bis-choline tetrathiomolybdate administration or (2) 70% or less than a normal platelet level; or

(iv) a neutrophil level of (1) 70% or less than a baseline neutrophil level measured before bis-choline tetrathiomolybdate administration or (2) 70% or less than a normal neutrophil level.

11. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises an alanine aminotransferase (ALT) level of at least five times that of a baseline ALT measured before bis-choline tetrathiomolybdate administration, and wherein:

(c) treatment is discontinued for a third period of time between step (a) and step (b) until the patient exhibits an alanine aminotransferase (ALT) level less than two times the baseline ALT measured before bis-choline tetrathiomolybdate administration; and optionally wherein the second dose in step (b) is 15 mg every other day.

12. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises an alanine aminotransferase (ALT) level of at least 200 IU/mL, and wherein:

(c) treatment is discontinued for a third period of time between step (a) and step (b) until the patient exhibits an alanine aminotransferase (ALT) level less than 68 IU/mL; and optionally wherein the second dose in step (b) is 15 mg every other day.

13. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises a hemoglobin level of less than 8 g/dl in the absence of bleeding, and wherein: (c) treatment is discontinued for a third time period between step (a) and step (b) until the patient exhibits a hemoglobin level equivalent to the hemoglobin level measured before bis-choline tetrathiomolybdate administration; and optionally wherein the second dose in step (b) is 15 mg every other day.

14. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises a platelet level of less than 30,000 UL, and wherein:

(c) treatment is discontinued for a third time period between step (a) and step (b) until the patient exhibits a platelet level equivalent to the platelet level measured before bis-choline tetrathiomolybdate administration; and optionally wherein the second dose in step (b) is 15 mg every other day.

15. The method of treating Wilson Disease according to claim 8 , wherein the abnormal test result comprises a neutrophils level of less than 1.0×10 3 /μL, and wherein:

(c) treatment is discontinued for a third time period between step (a) and step (b) until the patient exhibits a neutrophils level equivalent to the neutrophils level measured before bis-choline tetrathiomolybdate administration; and optionally wherein the second dose in step (b) is 15 mg every other day.

16. The method of treating Wilson Disease according to claim 8 , further comprising measuring at least one of said patient's:

a) alanine aminotransferase (ALT) level;

b) hemoglobin level;

c) platelets level; and

d) neutrophils level.

17. The method of treating Wilson Disease according to claim 3 , wherein the delayed release dosage form is a tablet, capsule, or an enterically coated tablet.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: CZLONKOWSKA, ANNA
To: INSTYTUT PSYCHIATRII I NEUROLOGII W WARSZAWIE
Reel/Frame 067866/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: INSTYTUT PSYCHIARTRII I NEUROLOGII W WARSZAWIE
To: WILSON THERAPEUTICS AB
Reel/Frame 067866/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: FERENCI, PETER
To: MEDIZINISCHE UNIVERSITAT WIEN
Reel/Frame 067866/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: MEDIZINISCHE UNIVERSITAT WIEN
To: WILSON THERAPEUTICS AB
Reel/Frame 067866/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: THE ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION TRUST
To: WILSON THERAPEUTICS AB
Reel/Frame 067866/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: WEISS, KARL HEINZ
To: UNIVERSITATSKLINIKUM HEIDELBERG
Reel/Frame 067867/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: UNIVERSITATSKLINIKUM HEIDELBERG
To: WILSON THERAPEUTICS AB
Reel/Frame 067867/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: ALA, AFTAB
To: THE ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION TRUST
Reel/Frame 067867/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: WILSON THERAPEUTICS AB
To: ALEXION BERMUDA L.P.
Reel/Frame 067868/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: ALEXION BERMUDA L.P.
To: ALEXION BERMUDA PARTNERS, LP
Reel/Frame 067868/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: ALEXION BERMUDA PARTNERS, LP
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 067869/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 067869/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: BJARTMAR, CARL; SCHILSKY, MICHAEL; ASKARI, FREDERICK; HEDERA, PETER
To: WILSON THERAPEUTICS AB
Reel/Frame 067963/0896 →
Continuity (9)
Continuation 16997928 · Aug 19, 2020
Continuation 16770022
Provisional Application 62750595 · Oct 25, 2018
Provisional Application 62741313 · Oct 4, 2018
Provisional Application 62669095 · May 9, 2018
Provisional Application 62655568 · Apr 10, 2018
Provisional Application 62646553 · Mar 22, 2018
Provisional Application 62594184 · Dec 4, 2017
Related Publication 20230070534A1 · Mar 9, 2023
References Cited (120)
US 7189865B2 · Ternansky et al. · 2007 [cited by applicant]
US 9623021B2 · Narayanan et al. · 2017 [cited by applicant]
US 11419832B2 · Bjartmar · 2022 [cited by examiner]
US 11510944B2 · Bjartmar · 2022 [cited by examiner]
US 20040019087A1 · Ternansky et al. · 2004 [cited by applicant]
US 20070207191A1 · Kanzer et al. · 2007 [cited by applicant]
US 20210093588A1 · Bjartmar et al. · 2021 [cited by applicant]
US 20210137972A1 · Bjartmar et al. · 2021 [cited by applicant]
US 20210177894A1 · Bjartmar et al. · 2021 [cited by applicant]
WO 2007084818A2 · 2007 [cited by applicant]
WO 2019110619A2 · 2019 [cited by applicant]
Brewer et al. “Initial Therapy of Patients With Wilson's Disease with Tetrathiomolybdate.” Arch. Neurol. 1991, 48, p. 42-47. [cited by applicant]
European Association for the Study of the Liver (EASL). “Clinical Practice Guidelines: Wilson's Disease.” J. Hepatology. 2012, 56, p. 671-685. [cited by applicant]
Weiss et al. “Bis-chloine tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.” Lancet Gastroenterol Hepatol. 2017, 2, p. 869-876. [cited by applicant]
Hellman et al. “Mechanisms of copper incorporation into human ceruloplasmin.” J. Biol. Chem. 2002, 48, pp. 46632-46638. [cited by applicant]
Czlonkowska et al. “Unified Wilson's Disease Rating Scale—a proposal for the neurological scoring of Wilson's disease patients.” Neurol Neurochir Pol. 2007, 41, p. 1-12. [cited by applicant]
Litwin et al. “Early neurological worsening in patients with Wilson's disease.” Neurol Sci. 2015, 335, p. 162-167. [cited by applicant]
Wiernicka et al. “Gastrointestinal side effects in children with Wilson's disease treated with zinc sulphate.” World J. Gastroenterol. 2013, 19, p. 4356-4362. [cited by applicant]
Wiess et al. “WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trail.” J. Hepatology. 2017, 66, p. S88. [cited by applicant]
Schilsky et al. “An ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients.” Hepatology. 2017, 66, p. 429A. [cited by applicant]
The International Liver Congress 2018 Abstract Book. “Posters Thursday, Apr. 12, 2018 ED—Zoulim, Fabien.” J. Hepatology. 2018, 68. [cited by applicant]
Müller et al. “Transition metal thiometalates: Properties and significance in complex and bioinorganics chemistry.” Angewandte Chemie, International Edition in English. 1981, vol. 20, p. 934-955. [cited by applicant]
Binnie et al. “On the preparation, properties, and structure of cuprous ammonium thiomolybdate.” Inorganic Chemistry. 1970, vol. 9, p. 1449-1452. [cited by applicant]
Laurie et al. “The copper-molybdenum antagonism in ruminants. III. reaction of copper(II) with tetrathiomolybdate (VI).” Inorganica Chimica Acta. 1986, vol. 123, p. 193-196. [cited by applicant]
Laurie et al. “Thiomolybdates—Simple but very versatile reagents.” European Journal of Inorganic Chemistry. 2000, p. 2443-2450. [cited by applicant]
Walshe et al. “Copper: Its role in the pathogenesis of liver disease.” Seminars in Liver Disease. 1984, vol. 4, p. 252-263. [cited by applicant]
Fabregues et al. “Ammonium tetrathiobolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series.” Brain and Behavior. 2020, vol. 10(e01596) p. 1-7. [cited by applicant]
Chandrasekaran et al. “Aging of ammonium tetrathiomolybdate(VI) in air: an example of induced electron transfer by external oxidant, oxygen.” Journal of the Less-Common Metals. 1987, vol. 134, p. L23-L25. [cited by applicant]
Ogra et al. “Metabolic fate of the insoluble copper/tetrathiomolybdate complex formed in the liver of LEC rats with excess tetrathiomolybdate.” Journal of Inorganic Biochemistry. 2000, vol. 78, p. 123-128. [cited by applicant]
Maiti et al. “Diverse biological roles of the tetrathiomolybdate anion.” Coordination Chemistry Reviews. 2021, ahead of publication, DOI: 110.1016/j.ccr.2020.213635. [cited by applicant]
Suttle et al. “Recent studies of the copper-molybdenum antagonism.” Proceedings of the Nutrition Society. 1974, vol. 33, p. 299-305. [cited by applicant]
Brewer et al. “Treatment of Wilson Disease With Ammonium Tetrathiomolybdate.” Arch Neurol, 2006, vol. 63, p. 521-527. [cited by applicant]
Brewer. “Tetrathiomolybdate anticopper therapy for Wiison's disease inhibits angiogenesis, fibrosis and flammation.” J. Cell. Mol. Med., 2003, vol. 7, No. 1, p. 11-20. [cited by applicant]
Weiss et al. “An Ongoing Phase 2 Multi-Centre Open Label Study of WTC101 in Newly Diagnosed Wilson Disease Patients—Early Obersavations.” Journal of Hepatology, 2016, vol. 64, supplement 2, p. S145-S146. [cited by applicant]
Roberts et al. “Diagnosis and Treatment of Wilson Disease: An Update”, AASLD Practice Guidlines, Hepatology, 2008, vol. 47, No. 6, p. 2089-2111. [cited by applicant]
Aggarwal et al. “Update on Wilson Disease”, In International Review of Neurobiology. Elsevier, 2013, vol. 110, p. 313-348. [cited by applicant]
Aggarwal et al. “Advances in Treatment of Wilson Disease”, Tremor and Other Hyperkinetic Movements, 2018, vol. 8, No. 525, p. 1-13. [cited by applicant]
Albarede et al. “Medical applications of Cu, Zn, and S isotope effects.” Metallomics, 2016, vol. 8, p. 1056-1070. [cited by applicant]
Alvarez et al. “Tetrathiomolybdate Inhibits Copper Trafficking Proteins Through Metal Cluster Formation.” Sciencexpress, 2009, 10.1126/science.1179907. [cited by applicant]
Alvarez et al. “Tetrathiomolybdate Inhibits Copper Trafficking Proteins Through Metal Cluster Formation.” Science, 2010, vol. 327, No. 5963, p. 331-334. [cited by applicant]
Avan et al. “Wilson's Disease Should be Treated with Zinc rather than Trientine or Penicillamine.” Neuropediatrics, 2017, vol. 48, No. 5, p. 394-395. [cited by applicant]
Brewer et al. “Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine.” Translational Research, 2009, vol. 154, No. 2, p. 70-77. [cited by applicant]
Chan et al. “Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration to healthy dogs.” AJVR, 2015, vol. 76, No. 5, p. 445-453. [cited by applicant]
Czlonkowska et al. “D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.” European Journal of Neurology, 2014, vol. 21, p. 599-606. [cited by applicant]
Czlonkowska et al. “Wilson's disease—cause of mortality in 164 patients during 1992-2003 observation period.” J. Neurol. 2005, vol. 252, p. 698-703. [cited by applicant]
Danks “Copper-induced dystonia secondary to cholestatic liver disease.” The Lancent, 1990, vol. 335, p. 410. [cited by applicant]
De Bie et al. “Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.” J. Med. Genet., 2007, vol. 44, p. 673-688. [cited by applicant]
Danks, D. M. “Chapter 68: Disorders of Copper Transport,” In The Metabolic and Molecular Bases of Inherited Disease, 7th ed.; Sriver, C.R,; Beaudet, A.L., Sly, W.S., Valle, D.; McGraw-Hill,:New York. 1995; p. 2211-2235. [cited by applicant]
Dyson et al. “Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models.” PLOS Medicine, 2017, https://doi.org/10… [cited by applicant]
Gibbs et al. “Liver copper concentration in Wilson's disease: Effect of treatment with ‘anti-copper’ agents.” Journal of Gastroenterology and Hepatology, 1990, vol. 5, p. 420-424. [cited by applicant]
Halverson et al. “A Mechanism for the Copper-Molybdenum Interrelationship.” J. Nutrition, 1960, vol. 71, p. 95-100. [cited by applicant]
Harada, M. “Pathogenesis and management of Wilson disease.” Hepatology Research, 2014, vol. 44, p. 395-402. [cited by applicant]
Harper et al. “Reversible Pancytopenia Secondary to Treatment with Tetrathiomolybdate.” British Journal of Haematology, 1986, vol. 64, No. 4, p. 851-853. [cited by applicant]
Hartard et al. “Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.” J. Neurol., 1993, vol. 241, p. 101-107. [cited by applicant]
Haywood, et al. “Metal (molybdenum, copper) accumulation and retention in brain, pituitary and other organs of ammonium tetrathiomolybdate-treated sheep.” British Journal of Nutrition, 1998, vol. 79, p. 329-331. [cited by applicant]
Hedera, P. “Updated on the clinical management of Wilson's disease.” The Application of Clinical Genetics, 2017, vol. 10, p. 9-19. [cited by applicant]
Hefter et al. “Long-term outcome of neurological Wilson's disease.” Parkinsonism and Related Disorders, 2018, vol. 49, p. 48-53. [cited by applicant]
Dalma, H. “Extrahepatic Manifestations of Wilson Disease.” Ph.D. Dissertation, Semmelweis University, Budapest, 2003. [cited by applicant]
Houwen, R. “Bis-choline tetrathiomolybdate for Wilson's disease.” Lancet Gastroenterol Hepatol, 2017, http://dx.doi.org/10.1016/S2468-1253(17)30325-4, p. 1-2. [cited by applicant]
Komatsu et al. “Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats.” Chemico-Biological Interactions, 2000, vol. 124, p. 217-231. [cited by applicant]
Li et al. “Current Drug Managements of Wilson's Disease: From West to East.” Current Neuropharmacology, 2016, vol. 14, p. 322-325. [cited by applicant]
Bega et al. “WTX101—A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study” Movement Disorders, Jun. 2017, vol. 32, S2, p. S455, Abstract 1184. [cited by applicant]
Sugawara et al. “Removal of Copper form the Liver of Long-Evans Cinnamon (LEC) Rats by Tetrathiomolybdate (TTM) Injection: The Main Excretion Route is via Blood, not Bile.” Research Communications in Molecular Pathology… [cited by applicant]
Sugawara et al. “The Effect of Subcutaneous Tetrathiomolybdate Administration on Copper and Iron Metabolism, Including their Regional Redistribution in the Brain, in the Long-Evans Cinnamon Rat, a bona fide Animal Model… [cited by applicant]
Sugawara et al. “Therapeutic Effects of Tetrathiomolybdate on Hepatic Dysfunction Occurring Naturally in Long-Evans Cinnamon (LEC) Rats: A Bona Fide Animal Model for Wilson's Disease.” Research Communications in Molecul… [cited by applicant]
Wang et al. “The Uptake and Intracellular Distribution of [35S] Trithiomolybdate in Bovine Liver In Vivo.” Journal of Inorganic Biochemistry, 1987, vol. 31, p. 85-93. [cited by applicant]
Wang et al. “Treatment of copper poisoning in goats by the injection of trithiomolybdate.” Small Ruminant Research, 1992, vol. 8, p. 31-40. [cited by applicant]
Wang et al. “Studies on the Uptake and Subsequent Tissue Distribution of [35S] Trithiomolybdate in Rats: Effects on Metallothionein Copper in Liver, Kidney, and Intestine.” Journal of Inorganic Biochemistry, 1988, vol. … [cited by applicant]
Zhang et al. “Effects of tetrathiomolybdate and penicillamin on brain hydroxyl radical and fee copper levels: A microdialysis study in vivo.” Biochemical and Biophysical Research Communications, 2015, vol. 458, p. 82-95. [cited by applicant]
Lozeron, P. et al., “Inhibitory rTMS applied on somatosensory cortex in Wilson's disease patients with hand dystonia.” J. Neural. Transm., vol. 124, No. 10, 2017, pp. 1161-1170. [cited by applicant]
Liu et al. “Epidemiology, diagnosis, and treatment of Wilson's disease.” Intractable & Rare Diseases Research, 2017, vol. 6, No. 4, p. 249-255. [cited by applicant]
Lorincz, M. T. “Chapter 18: Wilson disease and related copper disorders.” In Handbook of Clinical Neurology, Geschwind, D.H, Paulson, H.L, and Klein, C.; Elsevier, 2018, vol. 147 (3rd series), p. 279-292. [cited by applicant]
Mason, J. “Thiomolybdates: Mediators of Molybdenum Toxicity and Enzyme Inhibitors.” Toxicology, 1986, vol. 42, p. 99-109. [cited by applicant]
McQuaid et al. “A Comparison of the Effects of Penicillamine, Trientine, and Trithiomolybdate on [35S]-Labeled Metallothionein In Vitro; Implications for Wilson's Disease Therapy.” Journal of Inorganic Biochemistry, 199… [cited by applicant]
Medici et al. “Adverse Reaction after Tetrathiomolybdate Treatment for Wilson's Disease: A Case Report.” Movement Disorders, 2006, vol. 21, No. 11, p. 2030-2032. [cited by applicant]
Medici et al. “Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.” IDrugs, 2008, vol. 11, No. 8, p. 592-606. [cited by applicant]
Pfeiffer, R. F. “Wilson's Disease.” Seminars in Neurology, 2007, vol. 27, No. 2, p. 123-132. [cited by applicant]
Pierson et al. “The Function of ATPase Copper Transporter ATP7B in Intestine.” Gastroenterology, 2018, vol. 154, p. 168-180. [cited by applicant]
Roberts, E. A. “Update on the Diagnosis and Management of Wilson Disease.” Current Gastroenterology Reports, 2018, vol. 20, No. 56, p. 1-12. [cited by applicant]
Rodriguez-Castro et al. “Wilson's disease: A review of what we have learned.” World Journal of Hepatology, 2014, vol. 7, No. 29, p. 2859-2870. [cited by applicant]
Schilsky, M. L. “Diagnosis and Long-Term Management of Wilson Disease.” Gastroenterology & Hepatology, 2007, vol. 3, No. 1, p. 27-29. [cited by applicant]
Smirnova et al. “Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.” Scientific Reports, 2018, vol. 8, No. 1463, p. 1-9. [cited by applicant]
Stuerenburg, H. J. “CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease.” J. Neural Transm, 2000, vol. 107, p. 321-329. [cited by applicant]
Suzuki, et al. “Selective removal of copper bound to metallothionein in the liver of LEC rats by tetrathiomolybdate.” Toxicology, 1993, vol. 83., p. 149-158. [cited by applicant]
Suzuki et al. “Mechanisms for Removal of Copper form Metallothionein by Tetrathiomolybdate.” Journal of Inorganic Biochemistry, 1994, vol. 54, p. 157-165. [cited by applicant]
Suzuki et al. “Molybdenum and Copper Kinetics after Tetrathiomolybdate Injection in LEC Rats: Specific role of Serum Albumin.” J. Trace Elements Med. Biol., 1995, vol. 9, p. 170-175. [cited by applicant]
Walshe, J. M. “Tetrathiomolybdate (MoS4) as an anti-copper agent in man.” In Orphan Diseases and Orphan Drugs; Scheinburg, I. H., Walshe, J. M.; Manchester University Press, 1986; p. 76-85. [cited by applicant]
Walshe, J. M. “Wilson's Disease Patients Can Be Decoppered.” The Lancet, 1989, https://doi.org/10.1016/S0140-6736(89)90419-4, p. 228. [cited by applicant]
Walshe et al. “Chelation treatment of neurological Wilson's disease.” Quarterly Journal of Medicine, 1993, vol. 86, p. 197-204. [cited by applicant]
Walshe, J. M. “Monitoring Copper in Wilson's Disease.” Advances in Clinical Chemistry, 2010, vol. 50, p. 151-163. [cited by applicant]
Weiss et al. “WTX101—an investigational drug for the treatment of Wilson disease.” Expert Opinion on Investigational Drugs, 2018, vol. 27, No. 6, p. 561-567. [cited by applicant]
Woods et al. “Spectral and Kinetic Studies on the Binding of Trithiomolybdate to Bovine and Canine Serum Albumin in Vitro: The Interaction with Copper.” Journal of Inorganic Biochemistry, 1987, vol. 30, p. 261-272. [cited by applicant]
Allen et al. “Involvement of Organic Molybdenum Compounds in the Interaction between Copper, Molybdenum, and Sulfur.” Journal of Inorganic Biochemistry, 1986, vol. 27, p. 95-112. [cited by applicant]
Bremner et al. “Copper Metabolism in Rats Given Di- or Trithiomolybdates.” Journal of Inorganic Biochemistry, 1982, vol. 16, p. 109-119. [cited by applicant]
Comar et al. “Molybdenum Metabolism and Interrelationships with Copper and Phosphorus.” Journal of Biological Chemistry, 1949, vol. 180, No. 2, p. 913-922. [cited by applicant]
Czachor et al. “Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.” Journal of Inorganic Biochemistry, 2002, vol. 88, p. 213-222. [cited by applicant]
Dick et al. “Thiomolybdates and the copper-molybdenum-sulphur interaction in ruminant nutrition.” J. agric. Sci. Camb., 1975, vol. 85, p. 567-568. [cited by applicant]
Dick et al. “Some Preliminary Observations On The Effect Of Molybdenum On Copper Metabolism In Herbivorous Animals.” The Australian Veterinary Journal, 1945, vol. 21, p. 70-72. [cited by applicant]
George et al. “Tetrathiomolybdate causes formation of hepatic copper-molybdenum cluster in an animal model of Wilson's disease: Abstract.” J. Am. Chem. Soc., 2003, vol. 125, No. 7, p. 1704-1705. [cited by applicant]
Gooneratne et al. “An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep.” Br. J. Nutr., 1981, vol. 46, p. 469-480. [cited by applicant]
Gooneratne et al. “Intravenous administration of thiomolybdate for the prevention and treatment of chronic copper poisoning in sheep.” Br. J. Nutr., 1981, vol. 46, p. 457-467. [cited by applicant]
Gould et al. “Role of the rumen in copper and thiomolybdate absorption.” Nutrition Research Reviews, 2011, vol. 24, p. 176-182. [cited by applicant]
Howell et al. “Effect of Intravenously Administered Tetrathiomolybdate on Plasma Copper Concentrations of Copper-loaded Sheep.” J. Comp. Path., 1990, vol. 103, p. 321-334. [cited by applicant]
Humphries et al. “Use of ammonium tetrathiomolybdate in the treatment of copper poisoning in sheep.” The Veterinary Record, 1986, vol. 119, No. 24, p. 596-598. [cited by applicant]
Jones, H. B. “X-ray microanalysis of liver and kidney in copper loaded sheep with and without thiomolybdate administration.” Research in Veterinary Science, 1984, vol. 37, p. 273-282. [cited by applicant]
Ke et al. “Enhancement of tetrathiomolybdate-induced biliary copper excretion in sheep by general anaesthesia and the effect on copper excretion in urine and bile.” Research in Veterinary Science, 1989, vol. 46, p. 344-… [cited by applicant]
Klein et al. “Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease.” Journal of Hepatology, 2004, vol. 40, p. 409-416. [cited by applicant]
Kumaratilake et al. “Effects of intravenously administered tetra-thiomolybdate on the distribution of copper in the liver and kidney of copper loaded sheep: a histochemical study.” Research in Veterinary Science, 1987, … [cited by applicant]
Kumaratilake et al. “Intravenously Administered Tetra-thiomolybdate and the Removal of Copper from the Liver of Copper-loaded Sheep.” J. Comp. Path. 1989, vol. 101, p. 177-199. [cited by applicant]
Lannon et al. “The Inhibition of Bovine Ceruloplasmin Oxidase Activity by Thiomolybdates in Vivo an in Vitro: A Reversible Interaction.” Journal of Inorganic Biochemistry, 1986, vol. 26, p. 107-115. [cited by applicant]
Mason et al. “Accumulation of copper on albumin in bovine plasma in vivo after intravenous trithiomolybdate administration.” Research in Veterinary Science, 1986, vol. 41, p. 108-113. [cited by applicant]
Mason et al. “Studies of the changes in systemic copper metabolism and excretion produced by the intravenous administration of trithiomolybdate in sheep.” British Journal of Nutrition, 1988, vol. 59, p. 289-300. [cited by applicant]
Mills et al. “Copper and Molybdenum Absorption by Rats Given Ammonium Tetrathiomolybdate.” Journal of Inorganic Biochemistry, 1981, vol. 14, p. 163-175. [cited by applicant]
Ogra et al. “Systematic Dispositions of Molybdenum and Copper after Tetrathiomolybdate Injection in LEC Rats.” J. Trace Elements Med. Biol., 1995, vol. 9, p. 165-169. [cited by applicant]
Ogra et al. “Mechanism of selective copper removal by tetrathiomolybdate from metallothionein in LEC rats.” Toxicology, 1996, vol. 106, p. 75-83. [cited by applicant]
Ogra et al. “Effect of glutathion depletion on removal of copper from LEC rat livers by tetrathiomolybdate.” Journal of Inorganic Biochemistry, 2010, vol. 104, p. 858-862. [cited by applicant]
Ogra et al. “Removal and efflux of copper from Cu-metallothionein as Cu/tetrathiomolybdate complex in LEC rats.” Research Communications in Molecular Pathology and Pharmacology, 1995, vol. 88, No. 2, p. 196-204. [cited by applicant]
Reed et al. “Animals models of Wilson disease.” Journal of Neurochemistry, 2018, vol. 146, p. 356-373. [cited by applicant]
Song et al. “Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestic Liver Injury and Fibrosis.” Journal of Pharmacology and Experimental Therapeutics, 2008, vol. 325, No. 2, p. 409-4016. [cited by applicant]
Spence et al. “A Sequential Study of the Skeletal Abnormalities which Develope in Rats Given a Small Dietary Supplement of Ammonium Tetrathiomolybdate.” J. Comp. Path., 1980, vol. 90, p. 139-153. [cited by applicant]